Burkehill Global Management, LP
Position in DNLI — Denali Therapeutics Inc.
CIK 1904549
NEW YORK, NY
Position in DNLI
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,840,000
+$538,000 QoQ
Shares Held
200,000
0.0% QoQ
Ownership
0.126%
of shares outstanding
% of Portfolio
0.20%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Burkehill Global Management, LP holds $177,167,577 across 62 Biotechnology names. DNLI ranks #13 (2.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | COGT |
Cogent Biosciences, Inc.
|
675,000 | $25,980,750 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
35,000 | $11,276,650 | |
| 3 | RAPP |
Rapport Therapeutics, Inc.
|
250,000 | $7,822,500 | |
| 4 | NUVL |
Nuvalent, Inc.
|
70,000 | $7,171,500 | |
| 5 | TRVI |
Trevi Therapeutics, Inc.
|
525,000 | $6,263,250 | |
| 6 | KYMR |
Kymera Therapeutics, Inc.
|
75,000 | $6,246,750 | |
| 7 | CNTA |
Centessa Pharmaceuticals plc
|
150,000 | $5,958,000 | |
| 8 | XENE |
Xenon Pharmaceuticals Inc.
|
100,000 | $5,815,000 |
All Filings in DNLI
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,840,000 | 200,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,302,000 | 200,000 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||